<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-11-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09552</drugbank-id>
  <name>Thonzonium</name>
  <description>Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone.</description>
  <cas-number>25466-36-8</cas-number>
  <unii>Z05ZE98FV8</unii>
  <average-mass>511.818</average-mass>
  <monoisotopic-mass>511.437038827</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19494</ref-id>
        <pubmed-id>26906912</pubmed-id>
        <citation>Zhu X, Gao JJ, Landao-Bassonga E, Pavlos NJ, Qin A, Steer JH, Zheng MH, Dong Y, Cheng TS: Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016 Mar 15;104:118-30. doi: 10.1016/j.bcp.2016.02.013. Epub 2016 Feb 21.</citation>
      </article>
      <article>
        <ref-id>A19500</ref-id>
        <pubmed-id>20571174</pubmed-id>
        <citation>Deo AA, Kulkarni AS, Meshram SU: Monocationic surfactant induced ultra structural changes in antibiotic resistant Escherichia coli. Indian J Med Res. 2010 Jun;131:825-8.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L612</ref-id>
        <title>Pubchem</title>
        <url>https://pubchem.ncbi.nlm.nih.gov/compound/11102#section=Drug-Labels-for-Ingredients</url>
      </link>
      <link>
        <ref-id>L613</ref-id>
        <title>Wikipedia</title>
        <url>https://en.wikipedia.org/wiki/Thonzonium_bromide</url>
      </link>
      <link>
        <ref-id>L800</ref-id>
        <title>CORTISPORIN-TC Otic Suspension (Monarch) with Neomycin and Hydrocortisone</title>
        <url>https://www.drugs.com/drp/thonzonium-bromide.html</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used as a monocationic surfactant and detergent to help penetration of active ingredients through cellular debris for its antibacterial action.</indication>
  <pharmacodynamics>Thonzonium bromide causes dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the active ingredients contained in the administered medication. It is an inhibitor of vacuolar ATPase that uncouples and blocks the function of the pump without inhibiting ATP hydrolysis. </pharmacodynamics>
  <mechanism-of-action>Thonzonium bromide is a suface-active agent added in nasal and ear drops that potentiates and lenghten the time of skin contact with the active compounds and penetration through the cellular debris. &#13;
Thonzonium bromide uncouples vacuolar ATPase in pathogenic fungi such as *Candida albicans* and inhibit cell growth in vitro. It interacts with the tether of subunit a (Vph1p) of the membrane-bound V0 subunit that forms the proton transport path. Disruption of the essential pump function prevents redistribution of cytosolic protons into the vacuolar lumen, resulting in acidification of the cytosol and cell death [A19501]. &#13;
A study reports that thonzonium bromide mediates an antiresorptive action on osteoclasts by inhibiting RANKL-induced osteoclast formation. It is shown to block the RANKL-induced activation of NF-jB, ERK and c-Fos as well as the induction of NFATc1 which is essential for OC formation. It also disrupted F-actin ring formation resulting in disturbances in cytoskeletal structure in mature OCs during bone resorption [A19494]. </mechanism-of-action>
  <toxicity>Unwanted effects include irritation and allergic reactions. </toxicity>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.</description>
    <direct-parent>Anisoles</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Phenol ethers</class>
    <subclass>Anisoles</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Aminopyrimidines and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzylamines</alternative-parent>
    <alternative-parent>Dialkylarylamines</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Methoxybenzenes</alternative-parent>
    <alternative-parent>Organic cations</alternative-parent>
    <alternative-parent>Organic salts</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Tetraalkylammonium salts</alternative-parent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Amine</substituent>
    <substituent>Aminopyrimidine</substituent>
    <substituent>Anisole</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzylamine</substituent>
    <substituent>Dialkylarylamine</substituent>
    <substituent>Ether</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Methoxybenzene</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic cation</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Quaternary ammonium salt</substituent>
    <substituent>Tetraalkylammonium salt</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002554</drugbank-id>
      <name>Thonzonium bromide</name>
      <unii>JI2B19CR0R</unii>
      <cas-number>553-08-2</cas-number>
      <inchikey>WBWDWFZTSDZAIG-UHFFFAOYSA-M</inchikey>
      <average-mass>591.723</average-mass>
      <monoisotopic-mass>590.355925</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Tonzonium</synonym>
  </synonyms>
  <products>
    <product>
      <name>Coly-Mycin S</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0399</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-01</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA050356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Coly-Mycin S</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>42023-108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-01</started-marketing-on>
      <ended-marketing-on>2017-06-18</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA050356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Coly-Mycin S</name>
      <labeller>Endo Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63481-421</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-18</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA050356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cortisporin TC</name>
      <labeller>Endo Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63481-529</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA050356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cortisporin-TC</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA050356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cortisporin-TC</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42023-109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA050356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Cortisporin-TC</name>
      <ingredients>Colistin + Hydrocortisone acetate + Neomycin + Thonzonium</ingredients>
    </mixture>
    <mixture>
      <name>Coly-Mycin S</name>
      <ingredients>Colistin + Hydrocortisone acetate + Neomycin + Thonzonium</ingredients>
    </mixture>
    <mixture>
      <name>Coly-Mycin S</name>
      <ingredients>Colistin + Hydrocortisone acetate + Neomycin + Thonzonium</ingredients>
    </mixture>
    <mixture>
      <name>Cortisporin-TC</name>
      <ingredients>Colistin + Hydrocortisone acetate + Neomycin + Thonzonium</ingredients>
    </mixture>
    <mixture>
      <name>Cortisporin TC</name>
      <ingredients>Colistin + Hydrocortisone acetate + Neomycin + Thonzonium</ingredients>
    </mixture>
    <mixture>
      <name>Coly-Mycin S</name>
      <ingredients>Colistin + Hydrocortisone acetate + Neomycin + Thonzonium</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Ammonium Compounds</category>
      <mesh-id>D064751</mesh-id>
    </category>
    <category>
      <category>Nitrogen Compounds</category>
      <mesh-id>D017672</mesh-id>
    </category>
    <category>
      <category>Onium Compounds</category>
      <mesh-id>D009861</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Suspension</form>
      <route>Auricular (otic)</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09552.pdf?1496682839</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.07</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-7.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.82e-05 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.92</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>hexadecyl(2-{[(4-methoxyphenyl)methyl](pyrimidin-2-yl)amino}ethyl)dimethylazanium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>hexadecyl(2-{[(4-methoxyphenyl)methyl](pyrimidin-2-yl)amino}ethyl)dimethylazanium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>511.818</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>511.437038827</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C32H55N4O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C32H55N4O/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30/h19-25H,5-18,26-29H2,1-4H3/q+1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>IOYZYMQFUSNATM-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>38.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>171.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>66.44</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>3.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble </value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>91.5</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>94514</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5456</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827878</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5257</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>59083</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Thonzonium_bromide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201322</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004525</id>
      <name>V-type proton ATPase subunit C 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19501</ref-id>
            <pubmed-id>22215674</pubmed-id>
            <citation>Chan CY, Prudom C, Raines SM, Charkhzarrin S, Melman SD, De Haro LP, Allen C, Lee SA, Sklar LA, Parra KJ: Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). J Biol Chem. 2012 Mar 23;287(13):10236-50. doi: 10.1074/jbc.M111.321133. Epub 2012 Jan 3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P21283" source="Swiss-Prot">
        <name>V-type proton ATPase subunit C 1</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Subunit of the peripheral V1 complex of vacuolar ATPase. Subunit C is necessary for the assembly of the catalytic sector of the enzyme and is likely to have a specific function in its catalytic activity. V-ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.</specific-function>
        <gene-name>ATP6V1C1</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>43941.245</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:856</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21283</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>VATC1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP6C</synonym>
          <synonym>ATP6D</synonym>
          <synonym>V-ATPase subunit C 1</synonym>
          <synonym>Vacuolar proton pump subunit C 1</synonym>
          <synonym>VATC</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017461|V-type proton ATPase subunit C 1
MTEFWLISAPGEKTCQQTWEKLHAATSKNNNLAVTSKFNIPDLKVGTLDVLVGLSDELAK
LDAFVEGVVKKVAQYMADVLEDSKDKVQENLLANGVDLVTYITRFQWDMAKYPIKQSLKN
ISEIIAKGVTQIDNDLKSRASAYNNLKGNLQNLERKNAGSLLTRSLAEIVKKDDFVLDSE
YLVTLLVVVPKLNHNDWIKQYETLAEMVVPRSSNVLSEDQDSYLCNVTLFRKAVDDFRHK
ARENKFIVRDFQYNEEEMKADKEEMNRLSTDKKKQFGPLVRWLKVNFSEAFIAWIHVKAL
RVFVESVLRYGLPVNFQAMLLQPNKKTLKKLREVLHELYKHLDSSAAAIIDAPMDIPGLN
LSQQEYYPYVYYKIDCNLLEFK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017462|V-type proton ATPase subunit C 1 (ATP6V1C1)
ATGACTGAGTTCTGGCTTATATCTGCTCCTGGGGAGAAAACCTGTCAGCAAACATGGGAG
AAATTGCATGCGGCAACTTCAAAGAACAATAATCTTGCTGTCACTTCCAAGTTCAATATT
CCTGACTTAAAGGTTGGCACGTTGGATGTCTTGGTTGGCTTGTCAGATGAACTGGCTAAA
CTGGATGCATTTGTAGAAGGAGTGGTTAAGAAAGTAGCTCAATACATGGCTGATGTATTG
GAAGATAGCAAAGACAAAGTTCAAGAGAATCTGTTGGCTAATGGAGTGGACTTGGTTACT
TATATAACAAGGTTCCAGTGGGACATGGCCAAATATCCAATCAAGCAGTCCCTGAAAAAT
ATTTCTGAAATAATTGCCAAGGGAGTAACTCAGATTGATAATGACCTGAAATCTCGAGCA
TCTGCATACAATAACCTGAAAGGAAATCTTCAGAATTTGGAACGAAAGAATGCAGGAAGT
TTGCTAACTAGAAGTCTAGCAGAAATTGTGAAGAAGGATGACTTTGTTCTTGATTCAGAG
TATCTCGTCACATTACTGGTAGTAGTTCCCAAGTTAAACCACAACGACTGGATTAAGCAG
TATGAAACACTAGCCGAAATGGTAGTTCCAAGGTCTAGCAATGTTCTTTCAGAGGACCAA
GACAGTTACCTGTGTAATGTCACCTTGTTTAGGAAGGCAGTTGATGACTTCAGACACAAA
GCCAGAGAAAACAAATTCATTGTTCGTGACTTCCAGTATAATGAAGAGGAGATGAAAGCA
GATAAAGAAGAAATGAACAGGCTTTCTACTGATAAGAAAAAACAATTTGGACCACTTGTA
CGGTGGCTGAAAGTGAATTTTAGTGAAGCATTTATTGCATGGATTCACGTGAAAGCATTA
CGGGTTTTCGTTGAGTCTGTTTTAAGGTATGGCTTGCCAGTGAACTTCCAAGCAATGCTA
CTTCAGCCCAATAAGAAAACTTTGAAGAAACTGAGAGAAGTATTACATGAATTGTATAAA
CATCTAGACAGCAGTGCAGCAGCTATTATTGATGCTCCTATGGATATTCCAGGTTTAAAC
CTGAGTCAACAAGAATACTACCCCTATGTGTACTACAAGATTGATTGCAACTTGCTGGAA
TTCAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03223</identifier>
            <name>V-ATPase_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proton-transporting two-sector ATPase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proton-transporting V-type ATPase, V1 domain</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hydrogen-exporting ATPase activity, phosphorylative mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>proton-transporting ATPase activity, rotational mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ATP hydrolysis coupled proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phagosome maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transferrin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>